CollPlant Biotechnologies has secured a European patent allowance for its collagen-based formulations designed for use as soft tissue fillers and implants. The patent, effective until 2041, strengthens the company's position in the expanding aesthetic and reconstructive markets. This development is part of CollPlant's strategy to leverage its innovative rhCollagen technology for high-value applications, including injectable fillers and regenerative breast implants. The European patent covers a 3D biocompatible and degradable soft tissue implant, enhancing the competitiveness of its programs in strategic target markets.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。